On the way to a ‘Functional’ HIV Cure? Norway Vaccine clears viral load in 88% of Patients

11/07/2016 - 3 minutes

Oslo based Biopharma Bionor has a Phase I results for a HIV vaccine. The vaccine infusion rendered viral presence in 88% of patients undetectable after combination treatments with Celgene‘s enzyme inhibitor, Istodax and standard retroviral drugs. 

HIV bionor biotech aids vaccineThe positive results from the clinical trial REDUC Part B were published in the high impact journal The Lancet HIV.

The Norwegian’s proprietary vaccine works as a therapy in conjunction with other drugs to ‘work towards a functional HIV cure’.

The vaccine (Vacc-4x) was tested in a Phase Ib/2a trial in combination with Celgene’s Istodax (romidepsin), well known cancer specific cytotoxic protein. Adults who were infected with HIV and already receiving cART (combination anti-retroviral therapy) for over a year were recruited for the trial at the Aarhus University hospital in Denmark.

Vacc-4x is designed to induce CD4+ and CD8+ T-cell responses, to stimulate the immune system to remove HIV-infected cells.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member